Coronavirus: Digging into the Oxford-AstraZeneca COVID-19 vaccine candidate

Global News published this video item, entitled “Coronavirus: Digging into the Oxford-AstraZeneca COVID-19 vaccine candidate” – below is their description.

A COVID-19 vaccine being developed by the University of Oxford in collaboration with AstraZeneca Plc is producing a similar immune response in both older and younger adults, signaling hopes that the vaccine could be a frontrunner among the numerous vaccines in production and testing. Adverse responses were also lower among the elderly, adding more promise to the vaccine’s potential as a possible preventative measure against COVID-19. The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech’s candidate. Eric Sorensen reports. For more info, please go to Subscribe to Global News Channel HERE: Like Global News on Facebook HERE: Follow Global News on Twitter HERE: Follow Global News on Instagram HERE: #GlobalNews #COVID19 #coronavirus

Global News YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

In This Story: AstraZeneca

AstraZeneca plc/AB (LON: AZN) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America.

3 Recent Items: AstraZeneca

  • Your coronavirus vaccine questions, answered
  • Vaccine ‘hope’ for Africa, but challenges remain
  • How Long Will A Covid Vaccine Be Effective And Why Cold Storage Is Important | NBC News NOW
  • In This Story: BioNTech

    BioNTech SE (NASDAQ: BNTX) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases.

    5 Recent Items: BioNTech

  • AstraZeneca Covid Vaccine Draws Harsh Reviews from Wall Street Analysts
  • AstraZeneca-Oxford Vaccine Delivers But Can’t Match Pfizer and Moderna Results
  • Will enough people get vaccinated to stop spread of Covid? | DW News
  • Covid: First vaccine doses could be delivered next month @BBC News live – BBC
  • 1st vaccine nears finish line as COVID-19 numbers continue to rise
  • In This Story: COVID-19

    Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.

    Symptoms of coronavirus

    The main symptoms of coronavirus are:

    • a persistent new cough (non productive, dry)
    • a high temperature (e.g. head feels warm to the touch)
    • shortness of breath (if this is abnormal for the individual, or increased)

    Latest News about Covid-19

    Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.

    5 Recent Items: COVID-19

  • Sudan’s former prime minister Sadiq al-Mahdi dies of COVID-19
  • Abuse gone viral: How to stop online violence against women?
  • JPMorgan AM Favors Combination of Bonds, Riskier Assets
  • Coronavirus: Rebates to help save families hundreds in expenses | 9 News Australia
  • Covid: England’s regional tiers to be set out @BBC News live – BBC
  • In This Story: Pfizer

    Pfizer Inc. (NYSE: PFE) is an American multinational pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world’s largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

    5 Recent Items: Pfizer

  • Your coronavirus vaccine questions, answered
  • Russia says Sputnik V coronavirus vaccine 95 per cent effective
  • In full: Boris Johnson gives Downing Street press conference as local restrictions are unveiled
  • Astra-Oxford Vaccine Shows Two Different Efficacy Rates
  • AstraZeneca Covid Vaccine Draws Harsh Reviews from Wall Street Analysts
  • Leave a Comment